The FDA approved Febuxostat for the treatment of hyperuricemia

In February 16, 2009, the United States FDA approved nearly 40 years first for the treatment of hyperuricemia in gout drug. The febuxostat is produced by the Takeda pharmaceuticals North America. Febuxostat by reducing blood levels of uric acid in the blood of patients with gout symptoms improve.

According to a statement of Takeda's drug: the structure of febuxostat (CAS NO: 144060-53-7)

 is quite different from the structure of xanthine oxidase inhibitors developed 40 years ago, it is a kind of new and efficient non purine selective inhibitor of xanthine oxidase. Xanthine oxidase is the key enzyme of promoting the formation of uric acid. The Febuxostat can lower blood levels of uric acid in hyperuricemic gout patients, the efficacy and safety of febuxostat have been demonstrated in clinical studies. What’s more, in moderate to severe renal insufficiency patients do not need to adjust the dosage.

The dose of febuxostat 1 times a day, every 40 mg or 80 mg, but it is not recommended patients with gout but no high hyperuricemia to use febuxostat.

The original manufacturer of Febuxostat is another Japanese company - Japan Teijin Pharmaceutical. The president of the Teijin pharmaceutical companies had a recent statement; we can understand the company’s global strategy of febuxostat. He said, before the FDA in febuxostat license, the product of Ipsen Company has also obtained the approval of EU. Ipsen is about Benfeibusuotan Kyorin pharmaceutical in the EU's permission, Takeda Kitami pharmaceuticals is the product in the United States licensing company. The company has been in the global strategic sense of milepost type. At the same time, he also pointed out that, in the Asian market, Kyorin pharmaceutical will take the independent development or the form of joint development.

Gout is a heterogeneous group of disorders, hereditary and (or) to obtain the excretion of uric acid by reducing and (or) purine metabolic disorder. Clinical features: hyperuricemia, and urate crystal deposition characteristic, caused by acute arthritis, gout, interstitial nephritis, serious show joint deformity and function of dirty love. It is often associated with uric acid calculi. Pseudogout is often confused with gout, because its symptoms are very similar, then, pseudogout is caused by metabolic disorder of calcium phosphate, instead of uric acid metabolism disorder caused by.

According to the United States National Arthritis and musculoskeletal and skin diseases research institute (NIAMS) data showed that, there are 6000000, 20 years of age or older people experience the gout life in the United States of America. The male patients usually aged 40-50 is more common, and women with premenopausal rare. Experienced in organ transplant patients are also prone to gout. NIAMS points out that the drugs can increase the risk of gout: (1) the diuretic furosemide; hydrochlorothiazide; metolazone; (2) such as aspirin, salicylic acid; (3) nicotinic acid; (4) Cyclosporine Neoral; (5) Levodopa.

Frankie is the freelance writer for e-commerce website in the chemistry. Guidechem.com is just a place for you to look for some chemicals. Our guidechem provide the most convenient conditions for the international buyers and let these leads benefit all the business people. Guidechem chemical B2B network provides information on china and global chemical market quotation and relative chemical Information. Guidechem Chemical Network providing the most complete information of the chemical industry.